Drugs in Dev. Cardiology/Vascular Diseases
Phase I/ Phase II
France 
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia
Details : TOTUM-070 is a combination of plant extracts that contains neither phytosterols nor red yeast rice, designed by VALBIOTIS’ proprietary R&D platform based in Riom (63).
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VALBIOTIS expects to start a Phase II clinical trial evaluating the effect of TOTUM-070 in reducing LDL-cholesterol, in mild to moderate hypercholesterolemic patients.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 16, 2020
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hematopoetic Stem Cell
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand)
Details : Hematopoetic Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Myocardial Infarction.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 13, 2019
Lead Product(s) : Hematopoetic Stem Cell
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VAL070-A
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Biofortis Mérieux Nutriscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VAL070-A is a Dietary Supplement drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 12, 2016
Lead Product(s) : VAL070-A
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Biofortis Mérieux Nutriscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 99m-Tc Annexin V-128
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Advanced Accelerator Applications
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
Details : 99m-Tc Annexin V-128 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Endocarditis.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
June 02, 2015
Lead Product(s) : 99m-Tc Annexin V-128
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Advanced Accelerator Applications
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
